Quarterly ResultMay 12, 2026, 04:18 PM
Immunome Q1 Net Loss Widens to $53.8M; Cash $582.7M
AI Summary
Immunome Inc. reported a net loss of $53.8 million for the first quarter of 2026, widening from $41.6 million in Q1 2025, primarily due to increased research and development expenses and the termination of collaboration revenue. The company's cash and cash equivalents stood at $582.7 million as of March 31, 2026, down from $653.5 million at the end of 2025. Immunome expects its current cash to fund operations for at least 12 months, while continuing to invest in its targeted oncology therapies.
Key Highlights
- Net loss widened to $53.8 million in Q1 2026 from $41.6 million in Q1 2025.
- Collaboration revenue was $0 in Q1 2026, down from $2.9 million in Q1 2025.
- Research and development expenses increased to $46.4 million in Q1 2026 from $36.9 million in Q1 2025.
- General and administrative expenses rose to $13.0 million in Q1 2026 from $10.7 million in Q1 2025.
- Cash and cash equivalents totaled $582.7 million as of March 31, 2026.
- Net cash used in operating activities was $58.6 million in Q1 2026, up from $53.1 million in Q1 2025.
- Weighted-average shares outstanding increased to 113.1 million in Q1 2026 from 79.4 million in Q1 2025.
- Existing cash is expected to fund operations for at least 12 months from the filing date.
Price Impact
More from IMNM